Dear Colleague,

Myelodysplastic syndromes (MDS) and multiple myeloma (MM) remain among the more challenging cancers to manage. Although numerous single and combination treatment regimens have been explored in these diseases, morbidity and mortality remain high and new approaches are needed.

Recently, several new classes of agents – including proteasome inhibitors, methylation inhibitors, and immunomodulators – have shown promising results in treating patients with MDS and MM. It is essential for pharmacists involved in the care of patients with these disorders to keep apprised of both current and prospective therapeutic options. In this CE webcast, Pharmacist's Update on Myelodysplastic Syndromes and Multiple Myeloma, our panel of experts will discuss some of these exciting emerging drugs, focusing on their mechanisms of action, the management of related side effects and drug-drug interactions, and new strategies to incorporate these agents into existing treatment paradigms.

The presentations will address some of your most important concerns regarding these new agents and their role in improving outcomes in patients with these difficult-to-treat diseases. We hope you will join us for this informative and timely discussion.

Sincerely,

Deborah A. Blamble, PharmD
Chair

CHAIR

After participating in this activity, the clinician should be able to:

• Assess the etiology and natural history of MDS and MM to better manage these patients and improve patient morbidity and mortality.
  
  
• Apply a knowledge of MDS and MM patient risk level/stratification to determine the most appropriate therapeutic regimen.
  
  
• Based on mechanism of action, differentiate current and emerging therapies for MDS and MM to integrate these therapies into successful treatment strategies.
  
  
• Given the efficacy and safety of current and emerging therapies for MDS and MM, formulate strategies to improve patient responses and outcomes.
  
  
• Appraise toxicities, side effects, and drug-drug interactions for current and emerging therapies for MDS and MM to minimize their occurrence and improve patient compliance.

top

AGENDA

Myelodysplastic Syndromes: Emerging Treatment Options
Carlos M. de Castro, MD

New Paradigms in the Treatment of Multiple Myeloma
Jeffrey A. Zonder, MD

Managing MDS and MM Treatment-Related Toxicities/Drug Interactions and Improving Patient Compliance
Deborah A. Blamble, PharmD

Projects In Knowledge is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

 This activity has been planned and implemented in accordance with
 the ACPE Criteria for Quality and Interpretive Guidelines. The ACPE Universal
 Program Number assigned to this program, for 1 contact hour (0.1 CEU), is 052-000-05-004-H01.

The Disclosure Policy of Projects In Knowledge requires that presenters comply with the Updated Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.

For complete prescribing information on the products discussed during this CE activity, please see your current Physicians' Desk Reference (PDR).

Deborah A. Blamble, PharmD, has disclosed no significant relationships. Dr. Blamble has indicated that she will reference unlabeled/unapproved uses of arsenic trioxide, bortezomib, decitabine, lenalidomide, and thalidomide.

Carlos M. de Castro, MD, is a consultant and is on advisory boards for MGI Pharma, and is on the speakers bureau of Celgene Corporation and Pharmion Corporation. Dr. de Castro has disclosed that he will reference unlabeled/unapproved uses of amifostine, arsenic trioxide, cyclosporine A, cytarabine, daunorubicin, decitabine, doxorubicin, erythropoietin, filgrastim, imatinib mesylate, lenalidomide, lymphocyte immune globulin, prednisone, rubidazone, sargramostim, thalidomide, and thioguanine.

Jeffrey Zonder, MD, is on the speakers bureau of Celgene Corporation. Dr. Zonder has disclosed that he will reference unlabeled/unapproved uses of bortezomib, interferon alfa, lenalidomide, prednisone, thalidomide, and vincristine.

Peer Reviewer, is on the speakers bureau of Pfizer Inc.

Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust in Knowledge peer review process. The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.

This CE activity is provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the responsibility of the healthcare professional caring for the patient.

This independent CE activity is supported by an educational grant from Celgene Corporation.

Technical Requirements





Posttest & Evaluation

This independent CE activity
is supported by an
educational grant from
Celgene Corporation.